Medication info
Valsartan Tablets 80 mg (Valsartan)

Valsartan Tablets 80 mg (Valsartan)

Prescription medicationTabletOral
Ingredient · strength
Valsartan›80mg / 1 tablet
Manufacturer / importer
Genewon Science Co., Ltd.
Appearance
Pink round film-coated tablets
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 200809909 · Notified 2008.09.29 · Insurance code 671702870

Summary

Main use
Treatment of essential hypertension, reduction of the risk of death after myocardial infarction, and treatment of heart failure
Who takes it
Adults · Children
Adult dose
1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended to take this medication at the same time each day (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg per day or a diuretic may be administered concomitantly. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg per day. 2) Older adults (aged 75 years or older): Start treatment with 40 mg of this medication once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is needed. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medication once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medication. 4) Patients with reduced intravascular volume: In patients with reduced intravascular volume (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medication once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medication once daily, and do not exceed 80 mg per day. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medication orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medication, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction in the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this medication twice daily, followed over several weeks by dose increases to 40 mg, 80 mg, and 160 mg per dose twice daily, taking the patient's tolerability into consideration. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medication may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is needed if creatinine clearance is 10 mL/min or higher. However, do not administer this medication to patients with creatinine clearance below 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medication should preferably not exceed 80 mg. If administering 80 mg or more per day, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Child dose
1. Essential hypertension 6) Children: Safety and efficacy have not been established in children and adolescents under 18 years of age. 6. Children: Safety and efficacy have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Genewon Science Co., Ltd.

Efficacy & effects

Treatment of essential hypertension, reduction of the risk of death after myocardial infarction, and treatment of heart failure

  • Essential hypertension
  • heart failure
  • left ventricular failure
  • left ventricular systolic dysfunction
View approved original text

This medicine is used to control blood pressure in patients with essential hypertension. Additionally, it helps relieve symptoms of heart failure in patients who are intolerant to ACE inhibitors. For patients with myocardial infarction and symptoms or left ventricular dysfunction, it is used to reduce the risk of death after myocardial infarction. Therefore, this medication is effective for managing hypertension, treating heart failure, and preventing complications after myocardial infarction.

How to take

Adult dose

1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended to take this medication at the same time each day (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg per day or a diuretic may be administered concomitantly. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg per day. 2) Older adults (aged 75 years or older): Start treatment with 40 mg of this medication once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is needed. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medication once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medication. 4) Patients with reduced intravascular volume: In patients with reduced intravascular volume (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medication once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medication once daily, and do not exceed 80 mg per day. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medication orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medication, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction in the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this medication twice daily, followed over several weeks by dose increases to 40 mg, 80 mg, and 160 mg per dose twice daily, taking the patient's tolerability into consideration. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medication may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is needed if creatinine clearance is 10 mL/min or higher. However, do not administer this medication to patients with creatinine clearance below 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medication should preferably not exceed 80 mg. If administering 80 mg or more per day, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis.

Child dose

1. Essential hypertension 6) Children: Safety and efficacy have not been established in children and adolescents under 18 years of age. 6. Children: Safety and efficacy have not been established in children and adolescents under 18 years of age.

Precautions

This medication may cause serious harm to the fetus if taken during pregnancy, particularly in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. It should not be used by individuals who are allergic to this medication or its ingredients, pregnant women or those who may become pregnant, breastfeeding women, or patients with severe liver or kidney diseases. Caution should be exercised when using this medication in elderly patients or those with hyperkalemia, liver dysfunction, or heart valve disease, as it may cause blood pressure to drop too low. There is a risk of dizziness or fainting due to rapidly falling blood pressure, especially when starting the medication; extra caution is needed for patients currently on diuretics or dehydrated. While taking this medication, side effects such as headache, dizziness, cough, diarrhea, and fatigue may occur, and in rare cases, severe side effects like angioedema, hepatitis, or renal dysfunction may also arise. Regular blood tests may be required as serum potassium or kidney function levels may change. This medication may interact with other antihypertensive drugs, diuretics, or potassium supplements; patients must inform their doctor or pharmacist. Women who are pregnant or planning to become pregnant should not take this medication, and breastfeeding women should discontinue breastfeeding if they take this medication. The safety of this medication has not been established in children and adolescents; it should not be used in individuals under 18 years of age. In case of overdose, severe hypotension or altered consciousness may occur, so adherence to the prescribed dosage is crucial, and patients should seek medical attention for any unusual symptoms. This medication should be stored out of reach of children and not transferred to another container for safety purposes. Caution is necessary while driving or operating machinery, as dizziness or drowsiness may occur.

Side effects

headache

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air and moisture from entering. It is important to keep it in a cool place below 30 degrees Celsius to maintain its efficacy.

Appearance and packaging

Appearance

Pink round film-coated tablets

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.